Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world’s first biosimilar Ranibizumab

Lalit Verma, Mithun Thulasidas, Ajay Purohit, Avinindra Gupta, Ritesh Narula, Dinesh Talwar

Purpose: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of choriotretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular membrane (CNVM), and macular edema secondary to retinal vein occlusion (RVO). Methods: We conducted a single-center, retrospective study, including patients with DME, CNVM, and RVO, who had received treatment with Razumab® between October 2018 and September 2019. Primary outcome measures were the changes in corrected distance visual acuity (CDVA) and central foveal thickness (CFT) from baseline to 1 month and 3 months. Secondary outcome measures included intraocular pressure (IOP) at day 1, any signs of ocular inflammation or systemic adverse events during the follow-up. Results: One hundred and fifty-three eyes of 141 patients were analyzed. The indications included DME in 70 (45.8%) eyes, CNVM in 70 (45.8%) eyes, and RVO in 13 (8.4%) eyes. Mean CDVA improved from baseline (0.62 ± 0.44) to month 1 (0.45 ± 0.42) and maintained till 3 months (0.42 ± 0.44; P < 0.001). Mean CFT showed significant reduction from baseline (405.68 ± 192.42 mm) to month 1 (286.08 ± 118.36 mm) and month 3 (271 ± 104.24 mm; P < 0.001). None of the eyes recorded IOP >20 mmHg on day 1. No evidence of ocular toxicity or systemic adverse event was noted. Conclusion: Razumab® showed a rapid improvement in CDVA and CFT in most of the eyes with efficacy observed as early as 1 month and maintained till 3 months. The biosimilar Ranibizumab can be a safe and effective low-cost drug for treating macular diseases.

Key words: Biosimilar Ranibizumab, choroidal neovascular membrane, diabetic macular edema, Razumab, retinal vein occlusion

Retinal disease management has witnessed revolutionary advances in pharmacotherapy with the development of biological molecules that inhibit vascular endothelial growth factor (VEGF) such as Ranibizumab (Lucentis®; Genentech, South San Francisco, CA, USA/Roche, Basel, Switzerland), Aflibercept (Eylea®; Regeneron, Tarrytown, NY, USA), and less-expensive off-label Bevacizumab (Avastin; Genentech/Roche). Low cost and substantial success of Bevacizumab in the management of various retinal diseases including diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), and macular edema due to retinal vein occlusion (RVO) led to the widespread use of this off-label anti-VEGF drug. The efficacy of Ranibizumab for the primary treatment of retinal vascular diseases has been established in several studies. However, the high cost of Lucentis® (Ranibizumab) made it less affordable to many patients in developing countries including India.

Biosimilars are defined, according to the World Health Organization (WHO), as biotechnological products that are comparable with an already approved reference product in quality, nonclinical, and clinical evaluation. The world’s first biosimilar Ranibizumab, Razumab® was developed by Intas Pharmaceuticals Ltd., Ahmedabad, India, to provide a cost-effective alternative accessible to patients with retinal diseases, and it was approved by the highest Indian regulatory body, the Drug Controller General of India, in 2015. Razumab®, like its biologic reference product Lucentis®, is a recombinant humanized IgG1 monoclonal antibody fragment formulated for intraocular use. It comes in a single-use glass vial with a concentration of 10 mg/mL in 0.23 mL.

A prospective pilot study, including 95 patients, has initially demonstrated the efficacy and safety of Razumab® in Indian patients with choriotretinal vascular diseases. In addition to registration clinical trial, Intas also conducted RE-ENACT study (a retrospective pooled analysis) and RE-ENACT 2 study (long-term data) to assess the real-world experience of Razumab® in Indian patients with wet AMD, RVO, and DME.

We have conducted the Clinical Efficacy and SAFety of Razumab® (CESAR) study, which is a retrospective study with an independent design as opposed to that conducted by the developers of the biosimilar drug, to evaluate the use of Razumab® in Indian population with choriotretinal vascular diseases such as DME, choroidal neovascular membrane (CNVM), and macular edema secondary to RVO.

Methods

Study design

This single-center, retrospective study analyzed the data of patients who had received treatment with Razumab® at our vitreoretinal services, Centre for Sight, Safdarjung Enclave, New Delhi, India.

Correspondence to: Dr. Lalit Verma, Centre for Sight, B-5/24, Safdarjung Enclave, New Delhi, Delhi - 110 029, India. E-mail: lalitverma@yahoo.com

Received: 03-Aug-2020  Revision: 10-Sep-2020  Accepted: 17-Sep-2020  Published: 18-Jan-2021

© 2021 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow
eye hospital, between October 2018 and September 2019. The
institutional ethical committee approval was obtained, and the
tenets of the Declaration of Helsinki were followed for all study
procedures. The confidentiality of patients was maintained
throughout at all stages of the data analysis.

Study population
Patients who were administered Razumab® injection, both
treatment naïve or previously treated with other anti-VEGF/
stereoids/laser therapy, for DME, CNVM, or macular edema
secondary to RVO, were included in the study. Patients with
less than 3 months follow-up, dense cataract or corneal opacity,
ocular infection, previous vitrectomy, uncontrolled glaucoma,
and a history of myocardial infarction or cerebrovascular
accident were excluded.

Pro re nata (PRN; as needed) regimen without mandatory
loading doses was followed in all cases. Razumab® injection
was discontinued before 3 months if the corrected distance
visual acuity (CDVA) has reached 20/20 and central foveal
thickness (CFT) was less than 250 μm. Treatment was resumed
if CFT exceeded 250 μm and visual acuity dropped.

Intravitreal injection technique
Intravitreal injections were performed under strict aseptic
conditions under topical anesthesia in the operating room. 0.5
mg/0.05 mL of Razumab® solution was injected using a 30-gauge
needle (1 mL tuberculin syringe; DispoVan) inserted through
the pars plana, 4 mm posterior to the limbus in phakic eyes
and 3.5 mm in pseudophakic eyes. All patients received topical
antibiotic-steroid four times a day for a week after the injection.

Data collection
Demographic data collected from the records of the patients
included age, gender, eye laterality, clinical diagnosis, and any
previous treatment (anti-VEGF/stereoids/laser) for chorioretinal
vascular disease. Pre-injection clinical data included
CDVA (using Snellen’s chart), intraocular pressure (IOP; using
non-contact tonometer), and CFT measured by spectral-domain
optical coherence tomography (SD-OCT RTVue®, Optovue,
Inc., Fremont, CA). Post-injection data included IOP at day
1, CDVA, and CFT at 1 month and 3 months. Any systemic
adverse events, anterior segment/posterior segment signs of
inflammation throughout the follow-up period were checked.

Outcome measures
The primary outcome measures evaluated the efficacy of the
drug, which included the mean change in CDVA and CFT from
baseline to 1 month and 3 months. The secondary outcome
measures assessed the safety of the drug which included
any signs of toxicity or immunogenicity noted on clinical
examination such as anterior chamber reaction (cells/flare),
posterior segment inflammation (vitritis/snow balls/snow
banking/retinitis/retinal vasculitis) or systemic adverse events
during any of the follow-up visits. The mean change in IOP on
day 1 post-injection was also evaluated.

The CDVA measured by Snellen’s visual acuity chart
was converted to logarithm of the minimal angle of
resolution (logMAR) scale for statistical analysis. CFT was
defined as the distance between the internal limiting membrane
and the inner border of the RPE.

Statistical analysis
Statistical analysis was performed on the Statistical Package
for Social Sciences (SPSS) version 24.0 for Windows. Data
were summarized by the mean and standard deviation (SD).
Categorical variables were presented as frequency and
percentage. The normality of data was tested by the
Kolmogorov-Smirnov test. Repeated measures analysis of
variance (ANOVA) and paired t-test were performed to
compare the quantitative variables. P value less than 0.05 is
considered as significant at 95% confidence level.

Results
One hundred and fifty-three eyes of 141 patients (80 males and
61 females) were analyzed. The mean age was 67.01 ± 14.13 years,
ranging from 26 to 86 years. The majority (32.7%) of the patients
were in the age group of 71 to 80 years. The indications for
injection included DME in 70 (45.8%) eyes, CNVM in 70 (45.8%)
eyes, and RVO in 13 (8.4%) eyes. The mean number of biosimilar
Ranibizumab injections received was 2.67 ± 0.67 (range 1-3
injections) with 3 monthly injections received by 121 (79.1%)
eyes, 2 injections by 14 (9.1%) eyes, and 1 injection by 18 (11.8%)
eyes. The majority (79.1%) of the eyes were treatment naïve.
In previously treated eyes, the mean interval between the
last therapy and biosimilar Ranibizumab administration was
7.59 ± 4.74 months, ranging from 2-12 months. The baseline
characteristics of the patients are summarized in Table 1.

The mean logMAR CDVA of all the indications improved
significantly from 0.62 ± 0.44 (Median 0.5) to 0.42 ± 0.44 (Median
0.3) at the end of 3 months post-injection (P < 0.001) [Fig. 1].
Forty-five (29.4%) eyes had a gain of ≥ 2 lines of visual
acuity (Snellen’s chart). The CDVA improved in 97 (63.4%) eyes,
remained the same in 55 (35.9%) eyes, and worsened in 1 (0.7%)
eye. No patients had post-treatment loss of light perception.

A significant decrease in mean CFT was observed from
405.68 ± 192.42 μm at baseline to 271 ± 104.24 μm at the end of
3 months (P < 0.001) [Fig. 2]. Ninety-seven (63.4%) eyes had more
than 25% reduction in CFT in 69 (45.1%) eyes showing >100 μm
decrease in CFT from baseline. After injection, the CFT improved
in 148 (96.7%) eyes and worsened in 5 (3.3%) eyes. Tables 2 and 3
show the comparison of mean difference in CDVA and CFT from
baseline to month 1 and 3 after biosimilar Ranibizumab administration.

The mean difference between pre- and post-injection IOP
on day 1 was 1.58 ± 1.9 mmHg. Only five (3.3%) eyes had an
IOP rise ≥5 mm Hg. The mean post-injection IOP on day 1 was
14.8 ± 2.75 mmHg, with none of the eyes recording IOP ≥20 mm Hg.
No evidence of inflammation in the anterior or posterior segment
was noted during the follow-up period. None of the patients
developed serious ocular adverse effects such as endophthalmitis,
retinal/choroidal detachment, or optic atrophy. No systemic
adverse events were reported during any of the follow-up visits.

Of 121 treatment naïve eyes, 57 eyes had DME, 55 eyes
had CNVM, and 9 eyes had macular edema secondary to
RVO. A total of three biosimilar Ranibizumab injections
were received by 94 (77.7%) eyes, 2 injections by 9 (7.4%) eyes,
and 1 injection by 18 (14.9%) eyes. Significant improvement in
mean logMAR CDVA was observed from 0.60 ± 0.41 (Median
0.5) to 0.32 ± 0.32 (Median 0.2) in naïve DME eyes (P < 0.001),
0.64 ± 0.48 (Median 0.5) to 0.55 ± 0.54 (Median 0.3) in
naïve CNVM eyes (P < 0.001), 0.49 ± 0.40 (Median 0.3) to
0.21 ± 0.15 (Median 0.2) in naïve RVO eyes (P = 0.006) at the
end of 3 months [Fig. 3]. The mean CFT improved from
436.70 ± 174.33 μm to 273.04 ± 120.09 μm in naïve DME
eyes (P < 0.001), 367.58 ± 222.85 μm to 269.58 ± 105.72 μm in
naïve CNVM eyes (P < 0.001), 383.11 ± 202.36 μm to
231.44 ± 45.72 μm in naïve RVO eyes (P = 0.074) at 3 months
follow-up [Fig. 4].

Discussion
Anti-VEGF agents benefit patients with retinal vascular and
macular diseases as they are proven to improve vision and
prevent further vision loss resulting in better outcomes, prognosis,
and quality of life. Ranibizumab is a humanized, recombinant
monoclonal antibody fragment that binds to the receptor-binding site of active forms of VEGF-A, thereby preventing the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the endothelial cell surface, decreasing proliferation of endothelial cells, vascular leakage, and formation of new blood vessel.\(^{27}\) The clinical studies such as READ, RESOLVE, RESTORE, ANCHOR, MARINA, HORIZON, BRAVO, CRUISE, and RABAMES have already revealed both efficacy and safety of biologic Ranibizumab in patients with DME, neovascular AMD, and RVO.\(^{1-13}\)

The high cost of biologics has become a significant concern when it comes to healthcare costs in the management of retinal diseases. Biosimilars are molecules similar to existing innovator biologic reference products. However, they are large molecules derived from living cells, which could differ from the originator molecules and are not based on a fixed chemical formula. On the other hand, there is a possibility of biosimilar drugs being better than reference medicine due to the application of the latest technology by biosimilar companies compared to the technology used by innovator biologics. A biosimilar should prove comparable pharmacokinetics, pharmacodynamics, immunogenicity, safety, and efficacy to biologic reference drug to establish biosimilarity. Razumab® (Intas Pharmaceuticals Ltd., Ahmedabad, India) is the first and only approved biosimilar to Ranibizumab being used clinically at present.\(^{20}\) In this study, we have assessed the short-term (3 months) clinical efficacy and safety of Razumab® in patients with chorioretinal vascular diseases.

The present study showed that the visual acuity improved significantly as early as 1 month after the administration of biosimilar Ranibizumab injection. The mean logMAR CDVA improved from baseline (0.62 ± 0.44) to month 1 (0.45 ± 0.42; \(P < 0.001\)) and maintained till 3 months (0.42 ± 0.44; \(P < 0.001\)). Visual acuity worsened in only 1 patient with CNVM (from 20/200 to counting fingers) due to the development of foveal scar.

The mean CFT showed significant reduction from baseline (405.68 ± 192.42 \(\mu\)m) to month 1 (286.08 ± 118.36 \(\mu\)m; \(P < 0.001\)) and month 3 (271 ± 104.24 \(\mu\)m; \(P < 0.001\)). The percentage (%) change in CFT was 29.5% at 1 month and 33.2% at 3 months. However, the CFT increased or worsened in 5 (3 DME and 2 CNVM) eyes after injection. The presence of vitreomacular traction with associated proliferative diabetic retinopathy and large CNV size could be one of the reasons for persistent edema, leading to non-responsiveness.

In 121 treatment naïve eyes, the mean CDVA improved significantly from baseline to month 3 in each sub-group (DME,
The findings of this study are consistent with the data reported by Sharma et al. (RE‑ENACT study), and Sameera et al.[19‑26] The RE‑ENACT (REal life assessmENt of safety And effecTiveness of Razumab®) study conducted by the developers of the biosimilar drug (Intas Pharmaceuticals Ltd.) found significant improvements in visual acuity, central macular thickness, intra- and subretinal fluid with the use of the drug inpatients (n = 561) with wet AMD, DME, and RVO for a duration of 12 weeks.[21‑23] The RE‑ENACT 2 (n = 341) study evaluated the same variables for a longer‑term (48 weeks) in patients with wet AMD, DME, RVO, and additionally in patients with myopic CNVM.[24‑26] In the RE‑ENACT study, all patients received three biosimilar Ranibizumab injections, but the RE‑ENACT 2 study evaluated the patients who had been given one to five biosimilar Ranibizumab injections. Our study evaluated patients who had received one to three injections and observed a higher mean % change in CDVA (27.7%) and CFT (29.5%) at 1 month compared to RE‑ENACT study (pooled analysis) which showed a change of less than 5% at 1 month.[21] However, at 3 months follow‑up, the findings were almost similar between the studies. Regarding safety, both studies reported no serious adverse events.

Sameera et al. conducted a prospective study in Indian patients (n = 95) with wet AMD, DME, and RVO to evaluate the safety and efficacy of Razumab® for a duration of 1 month. They showed that biosimilar Ranibizumab treatment improved the visual acuity and central macular thickness with no ocular and systemic toxicity detected.[19]

Another retrospective study by Sharma et al. with a smaller sample size (n = 30) analysed the immunogenicity and efficacy after switching from biologic Ranibizumab to biosimilar Ranibizumab. No signs of immunogenicity and change in efficacy were noted at the end of 6 months. The reason for switching was due to financial constraints in all the cases.[19]

Because of their lower cost, biosimilars have the potential to reduce healthcare costs, thereby making it more accessible and affordable for a larger section of the patient population. Razumab® is available at 30‑40% reduced cost compared to reference biologic Ranibizumab in India and its user base has multiplied in the last few years.[20] Biosimilars have a potential advantage in developing countries like India, where insurance companies do not reimburse for anti‑VEGF agents, and compounding pharmacies are rare.[20] There is also a possibility of shift towards biosimilars in developed countries due to their low price. The insurance companies can have significant savings of 15‑20% due to multiple injections, and the government can save on the health expenditure too.[20]

Ocular inflammation has been reported for specific batches of Razumab® initially, putting a question on its safety and quality control.[20] The issues were resolved by discontinuing the production for a while, revising the manufacturing process, and delivering the subsequent batches with careful monitoring.[20] Though rare instances of severe ocular inflammation have been reported with innovator biologic products also, stricter pharmacovigilance and immunogenicity testing assay before market approval should be enforced to counteract the nocebo effect around the biosimilar drugs.[20‑23] The limitations of the study include its retrospective design and short‑term follow‑up of 3 months, though the study provides definite evidence of clinical efficacy and safety of the biosimilar Ranibizumab for the treatment of retinal vascular diseases. Prospective, randomized controlled trials with longer follow‑up are needed, which can provide more valuable information.

| Characteristics | n |
|-----------------|---|
| Number of eyes (patients) | 153 (141) |
| Age, mean±SD (years) | 67.01±14.13 |
| Gender, n (%) | |
| Male | 80 (56.7) |
| Female | 61 (43.3) |
| Indication, n (%) | |
| DME | 70 (45.8) |
| CNVM | 70 (45.8) |
| RVO | 13 (8.4) |
| Eye laterality, n (%) | |
| Right | 80 (52.3) |
| Left | 73 (47.7) |
| Treatment, n (%) | |
| Treatment naïve | 121 (79.1) |
| Previously treated | 32 (20.9) |
| Baseline CDVA, mean±SD (logMAR) | 0.62±0.44 |
| Baseline CFT, mean±SD (µm) | 405.68±192.42 |
| Baseline IOP, mean±SD (mmHg) | 13.22±2.44 |

Table 1: Baseline characteristics of the study population

SD: Standard deviation, DME: Diabetic macular edema, CNVM: Choroidal neovascular membrane, RVO: Retinal vein occlusion, CDVA: Corrected distance visual acuity, CFT: Central foveal thickness, IOP: Intraocular pressure.

| Mean difference in CDVA (logMAR) | Mean % change | Bonferroni P |
|----------------------------------|---------------|-------------|
| Baseline - 1 month | 0.17 | 27.7 | <0.01* |
| Baseline - 3 months | 0.20 | 31.8 | <0.01* |
| 1 month - 3 months | 0.03 | 5.7 | <0.01* |

Table 2: Comparison of mean difference in CDVA from baseline to month 1 and 3 after biosimilar Ranibizumab administration using post hoc analysis

CDVA: Corrected distance visual acuity, *Highly significant with level of significance: P<0.01 at 95% confidence limit

| Mean difference in CFT (µm) | Mean % change | Bonferroni P |
|-----------------------------|---------------|-------------|
| Baseline - 1 month | 119.59 | 29.5 | <0.01* |
| Baseline - 3 months | 134.68 | 33.2 | <0.01* |
| 1 month - 3 months | 15.08 | 5.3 | <0.01* |

Table 3: Comparison of mean difference in CFT from baseline to month 1 and 3 after biosimilar Ranibizumab administration using post hoc analysis

CFT: Central foveal thickness, *Highly significant with level of significance: P<0.01 at 95% confidence limit

CNVM, and RVO). The mean % change in CFT was 37% in naïve DME eyes, 26.7% in naïve CNVM eyes, and 39.6% in naïve RVO eyes at the end of 3 months. No evidence of toxicity or immunogenicity was noted after the intravitreal administration of biosimilar Ranibizumab. None of the eyes had an IOP >20 mmHg on day 1. Also, no systemic adverse events were reported up to 3 months follow‑up.
Conclusion

Our study demonstrates that the biosimilar Ranibizumab, Razumab® can be a safe and effective low-cost therapy in patients with chorioretinal vascular diseases such as DME, CNVM, and macular edema secondary to RVO. The data showed a rapid improvement in CDVA and CFT in most of the eyes with efficacy observed as early as 1 month and maintained till 3 months. The drug was well tolerated with no new safety issues over a period of 3 months.

Acknowledgements

The authors thank other CESAR Study investigators – Dr. Arindam Chakravarti, Dr. Saurabh Arora, Dr. Sonal Gupta, Dr. Anika Gupta, and Dr. Chitralekha De for their patient data contribution.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
2. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33.
3. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12.
4. Nguyen QD, Shah SM, Khwaja AA, Channa R, Heaf E, Do DV, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-51.
5. Massin P, Bandello F, Garweg JG, Hansen LI, Harding SP, Larsen M, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33:3299-305.
6. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615-25.
7. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789-801.
8. Suner IJ, Bressler NM, Varma R, Lee P, Dolan CM, Ward J, et al. Reading speed improvements in retinal vein occlusion after ranibizumab treatment. JAMA Ophthalmol 2015;133:851-6.
9. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9.
10. Pielen A, Mirshahi A, Felgen N, Lorenz K, Korb C, Junker B, et al. Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): Six-month results of a prospective randomized clinical trial. Acta Ophthalmol 2015;93:e28-37.
11. Pearce I, Banerjee S, Burton BJ, Chakravartthy U, Downey L, Gale RP, et al. Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-month, multicenter, phase II/III RELIGHT study. Ophthalmology 2015;122:1811-9.
12. Prunte C, Fajkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, et al. Ranibizumab 0.5 mg treatment and extend regimen for diabetic macular edema: The RETAIN study. Br J Ophthalmol 2016;100:797-95.
13. Payne JF, Wykoff CC, Clark WL, Bruce BB, Boyer DS, Brown DM, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREAT-DME 1 year outcomes. Ophthalmology 2017;124:74-81.
14. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies. Ophthalmology 2014;121:193-201.
15. Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247-54.
16. Korobelnik JF, Holz FG, Roeder J, Ogura Y, Simader C, Schmidt-Erfurth U, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: One-year results of the phase 3 GALILEO study. Ophthalmology 2014;121:202-8.
17. CATT Research Group, Martin DF, Maguire MG, Ying GS, Gruenwald JF, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
18. Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, et al. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: Real-world data. Eye 2020;34:1008-9.
19. Sameera VV, Apoorva AG, Joshi S, Guruprasad AS. Safety and efficacy of Razumab-The new biosimilar in India: Our experience. Kerala J Ophthalmol 2016;28:180-5.
20. Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: “Is there a big change on the horizon?” Clin Ophthalmol 2018;12:2137-43.
21. Sharma S; RE‑ENACT Study Investigators Group, Khan MA, Chaturvedi A. Real-life clinical effectiveness of Razumab® (world’s first biosimilar ranibizumab) in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: A retrospective pooled analysis. Int J Ophthalmol Eye Res 2018;6:377-83.
22. Sharma S; RE‑ENACT Study Investigators Group, Khan MA, Chaturvedi A. Real life clinical effectiveness of Razumab® (the world’s first biosimilar ranibizumab) in wet age-related macular degeneration: A subgroup analysis of pooled retrospective RE‑ENACT study. Int J Ophthalmol Eye Res 2018;6:368-73.
23. Sharma S, Khan MA, Chaturvedi A; RE‑ENACT Study Investigators Group. Real-life clinical effectiveness of Razumab® (the world’s first biosimilar ranibizumab) in wet age-related macular degeneration: A subgroup analysis of the pooled retrospective RE‑ENACT study. Ophthalmologica 2019;241:24-31.
24. Sharma S; RE‑ENACT 2 Study Investigators Group, Khan MA, Chaturvedi A. A multicenter, retrospective study (RE‑ENACT 2) on the use of Razumab® (World’s First Biosimilar Ranibizumab) in AMD, DME, RVO and Myopic CNV. J Clin Exp Ophthalmol 2019;10:826.
25. Sharma S, Khan M, Chaturvedi A; RE‑ENACT 2 Study Investigators Group. A multicenter, retrospective study (RE‑ENACT 2) on the use of Razumab® (World’s First Biosimilar Ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther 2020;9:103-14.
26. Sharma S; RE‑ENACT 2 Study Investigators Group, Khan M, Chaturvedi A. A multicenter, retrospective study (RE‑ENACT 2) on Razumab® (World’s First Biosimilar Ranibizumab) in Retinal Vein Occlusion [published online ahead of print, 2020 Jul 2]. Ophthalmol Ther 2020;10.1007/s40123-020-00277-3.
27. Klettner A, Roeder J. Comparison of Bevacizumab, Ranibizumab, and Pegaptanib in vitro: Efficiency and possible additional pathways. Invest Ophthalmol Vis Sci 2008;49:4523-7.
28. Sharma A, Kumar N, Kuppermann BD, Francesco B, Lowenstein A. Ophthalmic biosimilars: Lessons from India. Indian J Ophthalmol 2019;67:1384-5.
29. Available from: https://www.moneycontrol.com/news/business/companies/exclusive-complaints-prompt-intas-to-recall-batch-of-biosimilar-razumab-in-india-2251273.html. [Last accessed on 2020 Jul 25].
30. Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP. Severe ocular inflammation following ranibizumab or aflibercept injections for age-related macular degeneration: A retrospective claims database analysis. Ophthalmic Epidemiol 2016;23:71-9.